Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology
BioCentury This Week
00:00
The Importance of Good Data in Biotech
I think it's one of probably, I was going to say you went over a few of the numbers there and none of the numbers really look great for biotech heading into the second quarter. And so I think that's where this Prometheus acquisition is. It's a step obviously in the right direction. You know investors made money when they announced their phase two data in December when it jumped over 100%. So that's a pretty big premium on something that was already considered to be a takeout target.
Transcript
Play full episode
